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Abstract
Objective. This study aimed to investigate the effect of SagaPro, a product derived from Angelica archangelica leaf, on
nocturia.Material and methods. Sixty-nine male patients 45 years or older with at least two nocturnal voids were randomized
to receive SagaPro or placebo in a double-blind design for 8 weeks. Voiding diaries were assessed before and after the
treatment. Results. The results indicate that SagaPro is safe. The actual number of nocturnal voids (ANV), nocturnal
polyuria index (NPi) and nocturnal bladder capacity index (NBC index) decreased in the test population, but there was no
signiﬁcant difference between the treatment groups. Subsequent subgroup analysis showed that SagaPro signiﬁcantly
reduced the NBC index and nocturnal voids per sleeping hour in comparison to the placebo in participants with baseline
NBC index above 1.3. When participants with sleep disorders were excluded from this group, ANV was also signiﬁcantly
reduced for the SagaPro group in comparison to the placebo group. Conclusion. SagaPro, made from an extract of the
medicinal herb Angelica archangelica, is safe. This study did not show that SagaPro improved nocturia overall compared to
placebo. Subgroup analysis suggested a beneﬁcial effect in individuals with decreased nocturnal bladder capacity, which
warrants further study.
Key Words: angelica archangelica, nocturia, nocturnal bladder capacity index (NBC index), nocturnal polyuria index (NPi),
SagaPro.
Introduction
Nocturia is deﬁned as the need to wake from sleep one
or more times to void [1]. Having at least two voids
per night is associated with impaired health-
related quality of life [2]. The prevalence of nocturia
increases with increasing age in both men and
women. The bothersomeness of nocturia is largely
due to the fact that it interferes with the quality of
sleep, which may have a signiﬁcant negative impact on
how the individual feels the next day. Nocturia may
affect not only nocturics, but also their partners,
whose sleep may also be affected [3]. For patients
who are aged 60–70 years, the prevalence of nocturia
is between 11% and 50%; for those aged 80 years, the
prevalence is between 80% and 90%, with about 30%
experiencing two or more episodes nightly [4].
Important factors relating to nocturia include
benign prostate enlargement and overactive bladder,
diabetes mellitus, heart failure, renal failure, peripheral
oedema, nephrotic syndrome, hyperproteinaemia and
liver diseases [5]. The main causes of nocturia are
global polyuria, nocturnal polyuria, decreased bladder
capacity and sleep disorders [5]. Among the para-
meters used to assess the contribution of factors under-
lying nocturia are nocturnal polyuria index (NPi) and
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nocturnal bladder capacity (NBC) index [6]. The
NPi is usually calculated by dividing the nocturnal
urinary volume output by the total urinary output
and thus a high NPi indicates increased nocturnal
urine production. An NPi of 0.35 normally reﬂects
nocturnal polyuria [6], although the limit may be
lower or 0.2 for young people [7]. The NBC index
is calculated from the actual number of nightly voids,
nocturnal urine volume (nightly voided volume plus
the ﬁrst morning voided volume) and the functional
bladder capacity. A high NBC index, which reﬂects
reduced nocturnal bladder capacity, has been found
to be more prevalent among Asian men suffering
from nocturia than their Caucasian counterparts [8].
An NBC index of 1.3 has recently been suggested
as a cut-off point above which reduced nocturnal
bladder capacity should be investigated as a cause of
nocturia [9].
SagaPro is a phytochemical product from Angelica
archangelica leaf that has been used in Iceland for
6 years in the treatment of nocturia. The herb
A. archangelica has been used both in folk medicine
and as a vegetable. Extensive research has shown that
A. archangelica contains several important bioactive
compounds, including ﬂavonoids and other polyphe-
nols, terpenes, coumarins and polysaccharides, with
various biological effects [10–12]. The roots, fruits and
leaves of the herb have been used in folk medicine, and
it is one of the most respected medicinal herbs in
Nordic countries, where it was cultivated during the
Middle Ages [13,14] and exported to other parts of
Europe [15]. A water extract from A. archangelica
leaf, as is SagaPro, has been found to have antitumour
activity in vivo [16]. Among the many bioactive
phytochemicals present in SagaPro is isoquercitrin
(unpublished results), which could conceivably play
a role in the effect of SagaPro on nocturia experienced
by the users. Isoquercitrin is a ﬂavonoid that inﬂuences
the activity of leukotriene LTD4. Leukotrienes (LT)
are compounds which are derived from arachidonic
acid (20:4n-6) in smooth-muscle cells in the bladder
and cause contractions by stimulating receptors. LTD4
also causes contraction in coronary arteries, pulmonary
arteries and subcutaneous arterioles. Isoquercitrin
inhibits the activity of leukotrienes (LTD4), either by
inhibiting the production of LTD4 or by inhibiting
binding to receptors in smooth-muscle cells in the
bladder [17–19].
The purpose of this study was to examine the safety
of SagaPro and its therapeutic effect on nocturia.
Material and methods
Thiswas a parallel, randomized, double-blind, placebo-
controlled study to assess the effect of SagaPro on
nocturia in men. Included were 69 male volunteers,
45 years of age or older, with an average of at least
nocturnal voids per night as determined by a 3-day
voiding diary during the screening period.
Exclusion criteria were: residual urine volume
greater than 250 ml, total urine output over 24 h
exceeding an average of 3000 ml, abnormal urinary
ﬁndings suggestive of urinary tract infection, signif-
icant haematuria or glucosuria requiring further
evaluation, patients who had undergone surgical
treatment for bladder outlet obstruction/benign
prostatic hyperplasia (BPH) within the past
6 months, and patients with a history of urological
malignancy (e.g. bladder cancer, prostate cancer), a
medical history or active conditions, including
known neurological diseases which, in the opinion
of the investigators (PI) would prohibit participation
in the study. This included, but was not limited to,
cancer, renal failure, cirrhosis or chronic liver dis-
ease, pancreatic diseases, recent (< 6 months) myo-
cardial infarction or unstable coronary artery
disease. Also excluded were patients using medica-
tions affecting urination [e.g. loop diuretics (furo-
semide), antimuscarinic agents, ﬁnasteride or
dutasteride]. However, individuals who had been
using alpha-blockers were eligible for participation
in the study. A 7-day washout period was required
before starting recordings in the participant diary
used for baseline evaluation. Also excluded were
those using natural products used for BPH, such
as saw palmetto (Sabal serrulata or Serenoa repens),
those who had been using SagaPro or other products
containing A. archangelica within the 2 months prior
to randomization, patients with known allergy to
A. archangelica or any other ingredients of SagaPro,
patients who had received an investigational product
within 30 days before enrolment or expected receipt
during this study and men whose work or lifestyle
potentially interfered with regular night-time sleep,
e.g. shift workers.
Sixty-nine men were randomized to receive either
SagaPro or a matching placebo, two tablets per
day, and instructed to take the study product
in the evening, before going to bed. The tablets
were matched in appearance, having the same size
and colour coated to ensure blinding. Participants
were provided with diary forms to complete a
3-day voiding diary, recording time and volume
of voids (over 24 h), time when going to sleep
and wake-up time, deviations from planned study
product use, if any, and changes in health or
medication use, if applicable. The diaries were
completed before treatment (and were also used
for screening) and after approximately 8 weeks of
treatment.
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The nocturnal bladder capacity index was calcu-
lated as follows:
NBC index = ANV - PNV
where ANV is the actual number of nocturnal voids
and PNV is the predicted number of nocturnal voids:
PNV - = NUV FBC 1/
where NUV is the nocturnal urinary volume (nightly
voided volume plus ﬁrst morning voided volume) and
FBC is the functional bladder capacity, the maximum
voided volume in the 3-day diary.
The nocturnal polyuria index was calculated by the
formula:
NPi  NUV 24 h voided volume= /
A sample size of 70 participants was calculated to
provide a probability of at least 80% that the study
would detect a difference between SagaPro and pla-
cebo at a two-sided 5% signiﬁcance level, if the true
difference between the groups was 0.7 nocturnal voids
and the standard deviation of the response variable
was 1.0. The results are expressed as the mean and the
numerical changes from baseline values compared
statistically with the Student’s t test (two sided),
with differences between the treatment groups
considered signiﬁcant at p < 0.05.
The patients were fully informed and consented to
the study in writing. The study was approved by the
National Bioethics Committee of Iceland and the
Icelandic Medicines Agency.
Results
Of the total of 69 men, 66 completed the trial and
were included in the ﬁnal outcome. The clinical
characteristics of patients completing the trial are
shown in Table I.
Adverse events and safety
Blood pressure and heart rate were stable in both
groups during treatment. No severe adverse events
were reported, and the number of reports was similar
in both treatment groups, 24 in the placebo group and
21 in the SagaPro group. The adverse events were
mostly common conditions, the most frequent of
which were common cold (four in the placebo group
and three in the SagaPro group), diarrhoea (three in
each group), vomiting (two in each group) and sore
throat (two in the SagaPro group and one in the
placebo group). No other adverse events were
reported by more than one participant. In no case
was it found probable that the adverse event was
caused by the treatment, but it was found possible
in four cases (one in the placebo group and three in
the SagaPro group). One patient in the SagaPro group
discontinued treatment because of two of those
adverse events, bloating and weight gain, which
were later revealed to have been most probably due
to gallstones. The remaining adverse events found to
be possibly related to the treatment were constipation
(SagaPro) and diarrhoea (placebo). Adverse events
are listed in Table II.
Sleeping time
As sleeping time is bound to have a considerable
impact on the number of nocturnal voids, the sleeping
times were recorded in the diaries. The recorded
sleeping times preceding treatment (average of three
nights for each patient) ranged from 6 h 13 min to
11 h 32 min, with an average of 520 min. The average
sleeping time was reduced for both groups during
treatment, and more so in the placebo group,
although the treatment groups were not signiﬁcantly
different (p = 0.210) (Table III). This was used to
calculate nocturnal voids per sleeping hour by divid-
ing the actual number of nocturnal voids by the hours
of recorded sleeping time.
Effect of SagaPro on nocturia and related parameters
on the whole group
No signiﬁcant difference was found between the
treatment groups for ANV, nocturnal voids per
Table I. Initial clinical characteristics of patients ﬁnishing treatment.
n Average age and range (years) Average no. of nocturnal voids Patients with sleep disorders
Placebo 35 67.44 (47–85) 2.74 5
SagaPro 31 66.31 (49–86) 2.81 3
Table II. Number of adverse events related to the study drug.
Placebo SagaPro
Related to study drug n % n %
Probably 0 0.00 0 0.00
Possibly 1 4.17 3 14.29
Not related 23 95.83 18 85.71
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hour sleeping time, 24 hand nocturnal voided
volume, NPi or NBC index when the whole groups
were compared (Table IV).
Subgroup analysis
Subsequent subgroup analysis was carried out to
determine whether SagaPro had effect on nocturia
dependent on different underlying aetiology. To
study participants suffering from nocturnal polyuria,
the subgroup of 49 participants (22 from the SagaPro
group and 27 from the placebo group) with NPi above
0.35 was studied separately. No signiﬁcant difference
was found between the treatment groups (results not
shown).
To determine the effect of SagaPro on participants
with reduced nocturnal bladder capacity as a probable
cause for nocturia the effect of the herb on individuals
with low bladder capacity during the night-time was
analysed. As mentioned before, an NBC index of
1.3 has been suggested as a cut-off point above which
reduced nocturnal bladder capacity should be inves-
tigated as a cause of nocturia. Thus, the 36 partici-
pants with a baseline NBC index above 1.3 were
studied separately, as shown in Table V. For those
36 participants, voids per sleeping hour and NBC
index decreased signiﬁcantly more in the SagaPro
group (p = 0.034 and p = 0.044, respectively). Differ-
ences were seen for average and minimal volume per
nocturnal voids, both of which increased more in the
SagaPro group, albeit not signiﬁcantly.
As seen in Table V, the baseline values of the
treatment groups were very different for many para-
meters, including ANV, voids per sleeping hour and
NBC index. However, as seen in Figure 1, the effect is
not dependent on the baseline values, as the partici-
pants with the highest baseline values did not respond
better to treatment than those with lower initial
values.
When the seven patients with sleep disorders were
excluded from this group, the differences in reduced
voids per sleeping hour and NBC index became more
pronounced (p = 0.004 and p = 0.026, respectively),
with the reduction in ANV also being signiﬁcantly
(p = 0.02) more in the SagaPro group than in the
placebo group (Table VI).
Further studies on nocturnal bladder capacity
revealed that average and smallest nocturnal voided
volume increased signiﬁcantly (p = 0.042 and
p = 0.022, respectively) in the SagaPro group beyond
that of the placebo group for the subgroup of
43 patients with initial average nocturnal voided
volume less than 260 ml, whereas no differences
were found for the whole group (results not shown).
Discussion
The aim of this study was to investigate the safety of
SagaPro and its effect on the number of nocturnal
voids and underlying factors in men suffering from
nocturia.
The results indicate that SagaPro is safe. The
number of nocturnal voids decreased substantially
in the group as a whole, but no signiﬁcant difference
was found between the treatment groups, demon-
strating a considerable placebo effect.
SagaPro was tested on participants suffering from
nocturia of differing aetiology and severity. Apart
Table III. Average duration of sleep for both treatment groups with standard error of the mean and range.
SagaPro (n = 31) Placebo (n = 35)
Before After Before After
Average sleep (min) 508.1 ± 12.8 493.4 ± 13.7 532.1 ± 12.2 500.7 ± 10.8
Range (three-night average) 390–692 362–705 373–643 390–645
Table IV. Changes in main nocturia-related parameters for the treatment groups.
SagaPro (n = 31) Placebo (n = 35)
Before After % Change Before After % Change p
ANV 2.81 ± 1.06 1.98 ± 1.18 –29.5 2.74 ± 0.78 1.93 ± 1.040 –29.6 0.946
Voids per hour sleeping time 0.331 ± 0.104 0.235 ± 0.117 –29.0 0.311 ± 0.080 0.231 ± 0.122 –25.7 0.478
24 h voided volume (ml) 1817 ± 432 1645 ± 442 –9.5 1578 ± 349 1466 ± 440 –7.1 0.490
Nocturnal urine volume (ml) 784 ± 318 644 ± 194 –17.9 704 ± 226 586 ± 246 –16.8 0.694
NPi 0.426 ± 0.113 0.404 ± 0.124 –5.2 0.454 ± 0.121 0.404 ± 0.121 –11.0 0.292
NBC index 1.50 ± 0.70 1.02 ± 0.58 –32.0 1.58 ± 0.74 1.14 ± 0.71 –27.8 0.716
Data are shown as mean ± SD.
ANV = actual number of nocturnal voids; NPi = nocturnal polyuria index; NBC index = nocturnal bladder capacity index.
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from global polyuria, which was an exclusion criterion
in the study, the main causes of nocturia are nocturnal
polyuria, decreased bladder capacity and sleep
disorders [5]. Subsequent subgroup analysis aimed
to focus on patients with nocturia of different
aetiology.
Sleeping times, which contribute greatly to the
number of nocturnal voids, were also taken into
consideration and were found to be highly diverse
in this study, both between individuals and regarding
the average sleeping time over the treatment period.
Sleeping time was reduced in both groups, slightly
more in the placebo group, contributing to the reduc-
tion in the number of nocturnal voids. The reduced
sleeping time has no obvious explanation. To adjust
for this diversity, the number of nocturnal voids per
sleeping hour was calculated. This method is reason-
able for interpreting the data observed in this study
and is useful to overcome difﬁculties due to large
differences in sleeping time at night, especially in
small samples. For the group as a whole, the reduction
in nocturnal voids per sleeping hour was similar in
both treatment groups.
The NPi is used to indicate nocturnal polyuria
(increased urine production at night). An NPi of
0.35 normally reﬂects nocturnal polyuria [5], al
though the limit may be lower or 0.2 for young
people [8]. In this study, when participants with
NPi above 0.35 were studied separately, no signiﬁ-
cant difference was found between the treatment
groups.
An NBC index above 1.3 has been suggested as a
cut-off point above which reduced nocturnal bladder
capacity should be investigated as a cause of noc-
turia. Thus, in order to examine the effect on parti-
cipants with decreased nocturnal bladder capacity,
36 patients with an NBC index above 1.3 were
considered separately. In this subgroup, the NBC
index was signiﬁcantly reduced in the SagaPro
group, beyond that of the placebo group. Nocturnal
voids per hour were also signiﬁcantly reduced in the
SagaPro group. The baseline values are higher in the
SagaPro group; however, Figure 1 demonstrates that
Table V. Changes in nocturia-related parameters for the treatment groups for the 36 patients with nocturnal bladder capacity index (NBC
index) above 1.3 initially.
SagaPro (n = 12) Placebo (n = 24)
Before After % Change Before After % Change p
ANV 3.56 ± 1.34 2.26 ± 1.70 –36.5 2.90 ± 0.86 2.00 ± 0.95 –31.0 0.150
Voids per hour sleeping time 0.404 ± 0.126 0.251 ± 0.161 –37.9 0.332 ± 0.081 0.243 ± 0.111 –26.8 0.034
24 h voided volume (ml) 1991 ± 419 1804 ± 441 –9.4 1614 ± 345 1505 ± 460 –6.8 0.540
Nocturnal urine volume (ml) 853 ± 378 694 ± 244 –18.6 677 ± 234 560 ± 215 –17.3 0.578
NBC index 2.17 ± 0.70 1.25 ± 0.81 –42.4 1.85 ± 0.72 1.23 ± 0.72 –33.5 0.044
Average nocturnal voided volume 204 ± 82 269 ± 114 31.9 190 ± 67 222 ± 104 16.8 0.150
Smallest nocturnal volume voided 121 ± 51 231 ± 126 90.9 135 ± 53 190 ± 112 40.7 0.098
Data are shown as mean ± SD.
ANV = actual number of nocturnal voids.
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Figure 1. (A)Actualnumberofnocturnalvoids(ANV);(B)nocturnal
voids (NV) per hour sleeping time; and (C) and nocturnal bladder
capacity index (NBC index) before and after treatment, for the 36
participantswithbaselineNBCindex above1.3.TheSagaProgroup is
shownwith trianglesandtheplacebogroupwithcircles.Points lyingon
the equality line indicate no change after treatment, whereas points
lyingunder the line indicatea reductionandpoints lyingabove indicate
an increase during the treatment period.
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the reduction is not more pronounced in individuals
with high baseline values. It might be of interest to
examine further in another study the inﬂuence of
SagaPro on urodynamic parameters such as urinary
ﬂow and residual urine in a larger group of partici-
pants with nocturia and reduced bladder capacity.
The observed effect may, for example, be related to
changes in residual urine volume, which was only
measured before treatment in this study.
Sleep disorders can be an important primary cause
of nocturia [20]. Nocturnal voids due to sleep dis-
orders increase the number of nocturnal voids and
decrease the average void volume, and could thus lead
to an elevated NBC index, although the nocturnal
bladder capacity is not diminished. When patients on
sleep medication were excluded from this group, the
above-mentioned differences became more profound
and, in addition, the number of nocturnal voids,
independent of sleeping time, was signiﬁcantly
reduced in the SagaPro group beyond that of the
placebo group. The effect of SagaPro on participants
with an NBC index above 1.3 is also reﬂected in the
effect on the average and smallest nocturnal voided
volume.
SagaPro is a popular dietary supplement made from
an extract of the A. archangelica leaves. The product is
primarily used by men over the age of 50 who suffer
from lower urinary tract symptoms, to reduce noc-
turia and thereby improve sleep and general well-
being. The exact mechanisms of action of the reported
reduction in nocturia are not fully known at present
and further studies are needed. This clinical study was
carried out to examine the effect of SagaPro on
nocturia in men suffering from lower urinary tract
symptoms.
In conclusion, SagaPro, made from an extract of
the medicinal herb Angelica archangelica, is safe. This
study did not show that SagaPro improved nocturia
overall compared to placebo. Subgroup analysis
suggested a beneﬁcial effect in individuals with
decreased nocturnal bladder capacity, which warrants
further study.
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